Laurel Venture Capital
Focus on global innovation targets and original technologies
An early-stage innovative pharmaceutical investment institution dedicated to promoting the development of breakthrough life science technologies.
Laurel Venture Capital
Laurel Venture is a life science focused venture capital firm with a focus on venture and growth investment exclusively in therapeutic assets.
We aim to invest in early and mid-stage life science companies in China, Europe and the United States.
Let Life Science Technology Transfer.
We aim to fund companies that can deliver breakthrough medical advances with cutting-edge technology and strong IP profiles.
Laurel' s team of investors and entrepreneurs share a passion for the transformative power of technology to fulfil the unmet medical need.
Laurel Venture has a team of professionals and external consultants with extensive experience in finance, regulatory, IP, CMC, pre-clinical and clinical operations that engages strategically with our portfolio company Boards, management teams and co-investors to help secure successful corporate partnerships and exits.
The fund manager registration number of Laurel Venture Co., Ltd. in the China Securities Investment Fund Association is: P1071075
Recently, Laurel Venture Capital announced it has completed the acquisition of global rights to the S-Nitrosoglutathione Reductase (GSNOR) assets from Alpine Immune Sciences（NASDAQ:ALPN）. GSNOR serves a pivotal role in controlling nitric oxide availability within tissues and plays an important regulatory role in smooth muscle tone, immune function, inflammation and neuronal development. Disregulation of GSNOR has been implicated in disease and studies have shown pharmacologic GSNOR inhibition attenuates lung and systemic inflammation, decreases airspace enlargement in models of chronic obstructive pulmonary disease (COPD) and improves bronchoconstriction in asthma.
The availability of global technological innovations; the creation of a leading enterprise in the medical industry; the most powerful venture capital institution
The preferred partner for global technological innovation to enter the Chinese market to achieve value-added
Accelerate investment in blank potential sectors of China's medical industry and build high-quality platform companies
The organic combination of the scientific expertise, industry network and past performance of the two teams achieves overdue returns for investors
Integrate industrial resources and accelerate the process of company creation and development
Cangqian Street, Yuhang District, Hangzhou European and American Financial City (EFC), British Centre, T2-805
Post Code: 310000
Room 805, Building T2, EFC, Yuhang District, Hangzhou